DSM-Firmenich AG

DSM‑Firmenich’s new buy‑back, R&D focus and premium skin‑care, nutrition pipeline drive higher EPS and margin‑growth, positioning it for sustained success in a tightening ingredients market.

Mehdi Lisi’s move to Symrise signals a strategic shift in the fine‑fragrance market, blending DSM‑Firmenich’s sustainability and innovation expertise to boost competitiveness and regulatory readiness.

DSM‑Firmenich’s €540 m share‑repurchase program boosts EPS but hinges on tight margins and regulatory costs; investors weigh short‑term gains against long‑term risks.

DSM‑Firmenich’s non‑exclusive Osteopore deal unlocks Southeast Asia’s regenerative bone filler market, blending low‑capital growth with bio‑degradable innovation and 18‑22% ROIC.

DSM‑Firmenich’s Glycare 3SL 9001 gets regulatory clearance in China, Malaysia and Thailand—opening new growth in early‑life nutrition with a proven HMO ingredient.

DSM‑Firmenich’s 2026 restructuring slashes shares, sheds animal‑feed, and hones focus on nutrition, health and beauty—boosting EPS, ESG and long‑term growth.

DSM‑Firmenich’s 2025 report and dual‑tranche bond refinancing boost free cash flow, fund R&D and sustainability, and strengthen investor confidence amid regulatory scrutiny.

DSM‑Firmenich’s €1.5 bn bond issue and animal‑nutrition divestment sharpen focus on high‑margin nutrition, health & beauty, boosting long‑term value despite market caution.

DSM‑Firmenich sells its Animal Nutrition & Health unit for €2.2 bn to CVC, boosting free cash flow, raising margins, and refocusing on high‑growth flavours, fragrances and nutrients.

DSM‑Firmenich sells its Animal Nutrition & Health unit to CVC Capital Partners for €2.2 bn, keeping a minority stake and freeing capital to boost its nutrition, health and beauty businesses.